You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Bulk Pharmaceutical API Sources for CAPOZIDE 25/15


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for CAPOZIDE 25/15

Vendor Vendor Homepage Vendor Sku API Url
MuseChem ⤷  Get Started Free M013047 ⤷  Get Started Free
THE BioTek ⤷  Get Started Free bt-1172429 ⤷  Get Started Free
J&H Chemical Co.,ltd ⤷  Get Started Free JH57968 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for: CAPOZIDE 25/15

Last updated: July 30, 2025

Introduction

Capozide 25/15 is a combination pharmaceutical product containing 25 mg of captopril and 15 mg of hydrochlorothiazide (HCTZ). It is prescribed primarily to manage hypertension and congestive heart failure, leveraging the synergistic effects of an ACE inhibitor and a thiazide diuretic. The active pharmaceutical ingredients (APIs) — captopril and hydrochlorothiazide — form the foundation of this medication. Ensuring consistent, high-quality bulk API sourcing is vital for manufacturers to meet regulatory standards, optimize supply chain security, and maintain cost-effectiveness. This comprehensive review explores potential sources for these APIs, emphasizing quality, reliability, and compliance.

Global API Manufacturing Landscape

The global API manufacturing sector is extensive, driven by countries with established pharmaceutical infrastructure, notably India, China, South Korea, and parts of Europe and North America. These regions host a concentration of cGMP-compliant facilities capable of producing APIs suitable for commercial drug production. For Capozide 25/15, sourcing quality APIs involves evaluating suppliers based on regulatory compliance (FDA, EMA), manufacturing capacity, quality assurance measures, and supply stability.


Captopril API Sources

Overview

Captopril, an ACE inhibitor, was first introduced in the 1980s. Its synthesis involves complex chemical processes, necessitating stringent quality controls. Several manufacturers have established production lines, with India and China leading as major suppliers.

Leading Suppliers and Manufacturers

  1. Sun Pharmaceutical Industries Ltd. (India)
    Sun Pharma is recognized globally for its robust API manufacturing capabilities. The company produces high-quality captopril APIs conforming to USP and EP standards, with extensive cGMP compliance and FDA approvals for global markets.

  2. Aurobindo Pharma Ltd. (India)
    Aurobindo offers a broad portfolio of APIs, including captopril. Their facilities are certified by USFDA, EDQM, and other regulatory agencies, ensuring high-quality standards.

  3. Hetero Drugs Ltd. (India)
    Hetero maintains multiple GMP-certified manufacturing sites producing captopril APIs, serving both domestic and international markets with high purity levels.

  4. Pharmaceuticals China (Various Suppliers)
    China's capacity for API manufacturing spans multiple companies such as Zhejiang Huahai Pharmaceutical, with the ability to supply captopril at competitive prices, though careful vetting for regulatory compliance is essential.

  5. LKT Laboratories Inc. (USA)
    Although more renowned for research-grade APIs, LKT supplies pharmaceutical-grade captopril APIs for niche applications, primarily serving the North American market.

Regulatory & Quality Considerations

Suppliers must provide Certificates of Analysis (CoA), stability data, and validation documentation aligning with cGMP standards. Regulatory clearance from authorities such as FDA, EMA, or local equivalent is essential. Additionally, standardized testing for impurities, residual solvents, and endotoxins ensures API safety and efficacy.


Hydrochlorothiazide API Sources

Overview

Hydrochlorothiazide, a thiazide diuretic developed in the 1950s, remains a cornerstone in antihypertensive therapy. Its synthesis is well-established, producing high-purity APIs, with India and China dominating the manufacturing landscape.

Leading Suppliers and Manufacturers

  1. Dr. Reddy's Laboratories (India)
    Dr. Reddy’s manufactures hydrochlorothiazide API compliant with global standards, with an emphasis on purity, potency, and batch-to-batch consistency.

  2. Lupin Limited (India)
    Lupin’s facilities are certified by USFDA and EUGMP, providing high-quality hydrochlorothiazide APIs suitable for international formulations.

  3. Zhejiang Huadong Medicine Co., Ltd. (China)
    A leading Chinese API manufacturer, offering hydrochlorothiazide APIs at competitive prices while maintaining compliance with international pharmacopoeias.

  4. Wockhardt Ltd. (India)
    Wockhardt delivers a reliable supply of hydrochlorothiazide APIs, with extensive verification processes aligning with global regulatory requirements.

  5. MINSK INTERIM IMPORT-EXPORT LLC (Belarus)
    Produces hydrochlorothiazide for export, adhering to international pharmaceutical standards, with emerging presence in API supply chains.

Regulatory & Quality Considerations

Suppliers must demonstrate compliance with regulatory standards such as USP, EP, or BP monographs. Certification for Good Manufacturing Practices (GMP), comprehensive analytical validation data, and traceability are crucial for vetting APIs suitable for prescription products like Capozide.


Sourcing Strategies and Due Diligence

Global Supply Chain Risks

Global reliance on India and China for APIs presents risks related to geopolitical tensions, supply chain disruptions, and evolving regulatory landscapes. Diversifying suppliers and establishing long-term partnerships with multiple qualified vendors mitigates these risks.

Quality Assurance

It is imperative to conduct thorough supplier audits, request batch validation reports, and verify compliance standards. Some pharmaceutical developers prefer vendors with prior USFDA or EMA approval, ensuring adherence to internationally recognized quality benchmarks.

Regulatory Alignment

APIs should be sourced from suppliers capable of providing documentation aligned with the target market’s regulatory authority requirements. This includes Certificate of Origin, Certificates of Analysis, and drug master files if necessary.

Pricing and Lead Times

While Indian and Chinese suppliers dominate due to cost advantages, assessing lead times and logistical stability is essential. Engaging with suppliers offering reliable manufacturing schedules and contingency plans ensures uninterrupted API supply.


Future Outlook

Advances in manufacturing technology, regulatory harmonization, and global efforts on API quality standards are fostering a more resilient supply chain. The integration of robust quality systems and digital traceability will further enhance supplier reliability. For brands manufacturing Capozide 25/15, establishing relationships with certified API manufacturers ensures compliance, safety, and continuity.


Key Takeaways

  • Major API suppliers for captopril and hydrochlorothiazide are predominantly based in India and China, with reputable firms certified by international regulatory agencies.
  • Conduct comprehensive due diligence, including on-site audits, to verify quality and regulatory compliance.
  • Diversify API sources to mitigate geopolitical and supply chain risks.
  • Ensure APIs meet pharmacopoeial standards (USP, EP, BP) and possess proper validation documentation.
  • Monitor evolving regulatory landscapes to remain compliant and maintain supply chain integrity.

FAQs

1. What qualities should I look for in an API supplier for Capozide 25/15?
Suppliers should have GMP certification, regulatory approvals (FDA, EMA), consistent batch quality, comprehensive documentation, and a strong track record in API manufacturing.

2. Are Indian and Chinese API manufacturers reliable for cardiovascular APIs?
Yes, many Indian and Chinese manufacturers possess extensive experience, regulatory certifications, and high-quality facilities suitable for cardiovascular APIs like captopril and hydrochlorothiazide.

3. How can I mitigate supply chain disruptions when sourcing APIs internationally?
Diversify suppliers across regions, establish long-term contracts, maintain safety stock, and verify supply chain stability through regular audits and communications.

4. What regulatory considerations are involved when sourcing APIs for US and European markets?
Suppliers must provide certification and validation documentation compliant with USFDA, EMA, or local standards. APIs should meet pharmacopoeial monograph specifications and undergo rigorous testing for impurities.

5. How does API sourcing impact drug pricing and availability?
The quality, reliability, and costs associated with APIs directly influence drug pricing, formulation consistency, and market availability. Securing high-quality, competitively priced APIs ensures sustained supply and regulatory compliance.


References

[1] U.S. Food & Drug Administration. "API Import and Certification Guidelines," 2022.
[2] European Medicines Agency. "Guidelines on Good Manufacturing Practices for Active Substances," 2021.
[3] Pharmaceutical Technology. "Global API Manufacturing Landscape," 2022.
[4] Indian Pharmaceutical Alliance. "API Production and Regulatory Standards," 2023.
[5] China Food and Drug Administration. "API Regulatory Requirements," 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.